Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2052804 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL14691142 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL19506512 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL15353311 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL14691208 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL9184494 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL15353310 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL10389648 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL8583827 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL14690912 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190203196-A1 | COMPOSITIONS AND METHODS FOR PREPARING SHORT RNA MOLECULES AND OTHER NUCLEIC ACIDS | Life Technologies Corporation | 2019-07-04 | — | — | US | disclosed |
| US-20180073009-A1 | COMPOSITIONS AND METHODS FOR PREPARING SHORT RNA MOLECULES AND OTHER NUCLEIC ACIDS | Life Technologies Corporation | 2018-03-15 | — | — | US | disclosed |
| US-9670270-B2 | Minicell based delivery of biologically active compounds | VAXIION THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2216415-B2 | Methods for preparing short RNA molecules | LIFE TECHNOLOGIES CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160143844-A1 | Drug Delivery Systems and Use Thereof | MASSACHUSETTS EYE AND EAR INFIRMARY | 2016-05-26 | — | — | US | disclosed |
| EP-2155239-B1 | METHOD FOR TREATING MULTIPLE SCLEROSIS USING NEUTRALIZING ANTI-S1P ANTIBODIES | LPATH INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20150218254-A1 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | VAXIION THERAPEUTICS, LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2272946-B9 | Minicell compositions and methods | VAXIION THERAPEUTICS LLC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-9017986-B2 | Minicell based delivery of biologically active compounds | VAXIION THERAPEUTICS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2272946-B1 | Minicell compositions and methods | VAXIION THERAPEUTICS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2002074787-A2 | COMPOSITIONS AND METHODS FOR IDENTIFYING, CHARACTERIZING, OPTIMIZING AND USING LIGANDS TO TRANSCYTOTIC MOLECULES | ARIZEKE PHARMACEUTICALS, INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002051439-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES AND DISORDERS, AND FOR IDENTIFYING AGENTS THERAPEUTIC THEREFOR | MEDLYTE, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002028408-A2 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF BIOLOGICALLY ACTIVE AGENTS ACROSS CELLULAR BARRIERS | ARIZEKE PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-1999010365-A2 | 5',5'-LINKED OLIGOMERS HAVING ANTI-THROMBIN ACTIVITY | GILEAD SCIENCES, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5756291-A | IDENTIFYING OLIGOMER SEQUENCES; QUALITATIVE ANALYSIS; ANALYSIS OF THROMBIN BY COMPLEXING | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1996008559-A1 | GLYCOSAMINOGLYCAN-DEGRADING ENZYME INHIBITION AND RESULTANT DISEASE THERAPIES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1996-03-21 | — | — | WO | disclosed |
| EP-0572529-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992014843-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| US-4914233-A | Synthesis of beta-thymidine | ETHYL CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218254-A1 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | PCNA, PAICS, TOP1 | GAA 1476/4885L3MBTL1 1117/4885MAPT 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.